Screening for human ADME/Tox drug properties in drug discovery.
about
Toxic hepatitis in occupational exposure to solventsIs There a Space-Based Technology Solution to Problems with Preclinical Drug Toxicity Testing?μOrgano: A Lego®-Like Plug & Play System for Modular Multi-Organ-ChipsBiopharmaceutical characterization of decursin and their derivatives for drug discoveryDevelopment of in vitro 3D TissueFlex® islet model for diabetic drug efficacy testingAntibiotic toxicity and absorption in zebrafish using liquid chromatography-tandem mass spectrometryNovel paradigms for drug discovery: computational multitarget screeningCan the Internet help to meet the challenges in ADME and e-ADME?A sandwiched microarray platform for benchtop cell-based high throughput screening.Metabolizing enzyme toxicology assay chip (MetaChip) for high-throughput microscale toxicity analyses.Effects of synthetic androgens on liver function using the rabbit as a modelProfiling of toxicity and identification of distinct apoptosis profiles using a 384-well high-throughput flow cytometry screening platform.Virtual screening using molecular simulations.Deficiencies in the reporting of VD and t(1/2) in the FDA approved chemotherapy drug inserts.Predicting pharmacokinetics and drug interactions in patients from in vitro and in vivo models: the experience with 5,6-dimethylxanthenone-4-acetic acid (DMXAA), an anti-cancer drug eliminated mainly by conjugation.Interactions of herbs with cytochrome P450.PharmGED: Pharmacogenetic Effect Database.pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures.Divide and Conquer May Not Be the Optimal Approach to Retain the Desirable Estrogenic Attributes of the Cyclopia Nutraceutical Extract, SM6Met.Influence of verapamil on pharmacokinetics of pristimerin in rats.Functional and cytometric examination of different human lung epithelial cell types as drug transport barriersFunctionalized Benzimidazole Scaffolds: Privileged Heterocycle for Drug Design in Therapeutic Medicine.Prediction of drug metabolism and interactions on the basis of in vitro investigations.Gomisin A is a Novel Isoform-Specific Probe for the Selective Sensing of Human Cytochrome P450 3A4 in Liver Microsomes and Living Cells.Selection of suitable prodrug candidates for in vivo studies via in vitro studies; the correlation of prodrug stability in between cell culture homogenates and human tissue homogenatesApplicability of the Rayleigh equation for enantioselective metabolism of chiral xenobiotics by microsomes, hepatocytes and in-vivo retention in rabbit tissues.Knowledge-Based Methods To Train and Optimize Virtual Screening Ensembles.Maximising use of in vitro ADMET tools to predict in vivo bioavailability and safety.Neurobiological applications of small molecule screening.Comparative analysis of AhR-mediated TCDD-elicited gene expression in human liver adult stem cells.Study of in-vitro metabolism of selected antibiotic drugs in human liver microsomes by liquid chromatography coupled with tandem mass spectrometryApplication of mechanism-based CYP inhibition for predicting drug-drug interactions.Pharmacological approaches to restore mitochondrial function.Recent development in high-throughput bioanalytical support for in vitro ADMET profiling.Autonomously bioluminescent mammalian cells for continuous and real-time monitoring of cytotoxicity.Toward a new age of cellular pharmacokinetics in drug discovery.Recent progress in tight junction modulation for improving bioavailability.Scientific concepts and applications of integrated discrete multiple organ co-culture technology.Distinguishing between the permeability relationships with absorption and metabolism to improve BCS and BDDCS predictions in early drug discoveryAdvantages of Structure-Based Drug design Approaches in Neurological Disorders.
P2860
Q22305492-2ADBD8A7-18A6-4FD3-91D6-9E581B990BF1Q26749381-1B53AA7B-B345-44BE-8CA2-A13BF61B23D6Q27315172-8A4CB749-E61F-4E15-B5DB-316877B3F348Q28275658-EED8EE39-E7EB-4FA3-9A0D-07BD6AC60EFCQ28535375-CEBF4870-65A9-4AD3-B22A-98D524E9A6E2Q28546965-15497AF3-A2FC-46DA-8C60-20F480A5587AQ30662767-EF4D0C20-1F5B-4D29-9046-2B2C57F12966Q31104637-96BA43F2-F50C-4401-97B3-F9CC90544C9CQ33724982-56766E80-5752-4ED0-A1A5-B2A4FE277D40Q33762518-E9B14601-6FE3-4290-8ABA-0C365985CE7DQ34109318-EAF599E0-ACB4-45D4-99F9-C178790DF388Q34229423-858B75DC-FD51-491E-86F1-94A37172F305Q34975702-95486503-A5CE-4B99-B58F-4679EB430956Q35020052-36BF264C-FF7C-4FD0-AB40-D6E9D894DD0EQ35027930-65852FF1-80B9-4B04-9DFF-27B1D0621175Q35085032-02347F93-A138-416F-B83B-CE4F417002D5Q35567962-3DAE9F84-2697-447B-8C3F-DE93F96FA648Q35599192-31F5CA71-3490-4DCF-BDE2-F4FF652278FFQ35712301-14AAAE41-77DC-4644-B0C7-A69BFB5AF5E7Q35766574-69491874-AF19-48BF-8EAF-059A635F20DDQ35889102-84BA75A3-943A-4704-9AA1-52A7EDD8963EQ36026159-B6F1E6B0-B00E-4DD0-8745-A58B166D5DC8Q36055562-58769A42-0F46-45C9-A4F0-88FF2939D34DQ36445096-D9EC5255-CFE9-461D-B3E5-89DA9B43E47DQ36631747-8A15C31A-A5E5-4C79-8EA1-C11A8E396B07Q36735906-B5D6F2A8-C280-4C75-831B-0E4F7F68ADA1Q36938240-1460E1B7-635C-41D2-B4D5-08444502591AQ36960535-FEF63406-ABD4-4590-82B5-31947E9980DAQ37151213-E8993510-7A47-41B0-9A0C-44A73DC27AB1Q37402821-32DCE679-AF37-4E48-98D3-941023D06A2DQ37424175-C7720343-C30C-4AE3-A055-18E11BAE46E4Q37494640-A0C8DE87-5AAB-44B5-A53B-12F3E65854BCQ37497833-54DE90FB-56F4-4756-89BF-DD3B7C43E1B0Q37693962-E922F52C-93EB-4715-813D-CDC147FD9A1EQ37715781-F5B35A1E-ECCF-4AAF-8C2C-5193CCBEEBB3Q37851981-F24584CD-FF8C-4836-AA30-B8CC19AB3D22Q38190079-5E705ADA-6074-4735-AB37-3C6FC09E65D2Q38476999-CF1EF689-F081-449C-9D31-1B389869B262Q38705829-204DD174-F75E-4C61-B09A-EEB6F1A035BFQ38775661-0A95213E-475E-4EA6-9FF8-8B325B3E15DF
P2860
Screening for human ADME/Tox drug properties in drug discovery.
description
2001 nî lūn-bûn
@nan
2001 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Screening for human ADME/Tox drug properties in drug discovery.
@ast
Screening for human ADME/Tox drug properties in drug discovery.
@en
Screening for human ADME/Tox drug properties in drug discovery.
@nl
type
label
Screening for human ADME/Tox drug properties in drug discovery.
@ast
Screening for human ADME/Tox drug properties in drug discovery.
@en
Screening for human ADME/Tox drug properties in drug discovery.
@nl
prefLabel
Screening for human ADME/Tox drug properties in drug discovery.
@ast
Screening for human ADME/Tox drug properties in drug discovery.
@en
Screening for human ADME/Tox drug properties in drug discovery.
@nl
P1433
P1476
Screening for human ADME/Tox drug properties in drug discovery.
@en
P304
P356
10.1016/S1359-6446(01)01712-3
P50
P577
2001-04-01T00:00:00Z